Health Canada has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide injection as an adjunct to diet and exercise that can help adults with Type II diabetes control their blood sugar levels.
The drug, Ozempic, is a GLP-1 receptor agonist and won FDA approval in the U.S. in December.
Get the full story at our sister site, Drug Delivery Business News.